Navigation Links
Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
Date:5/9/2011

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2011.  For the three months ended March 31, 2011, Orexigen reported a net loss of $11.6 million, or $0.24 per share, as compared to a net loss of $14.1 million, or $0.30 per share, for the first quarter of 2010.  As of March 31, 2011, Orexigen had $39.6 million in cash and cash equivalents and an additional $36.9 million in marketable securities, for a total of approximately $76.6 million.

"Over the last several months, together with our partner, Takeda, and our external advisors, we have been preparing for a meeting with FDA to discuss a viable path forward for Contrave®," said Michael Narachi, president and CEO of Orexigen. "We have submitted to the Agency a specific, innovative, and robust proposal to assess cardiovascular risk and have confirmed a meeting with the Agency later this quarter to discuss our proposal."

Total operating expenses for the first quarter of 2011 were $13.3 million compared to $14.0 million for the first quarter of 2010. This decrease in operating expenses primarily reflects a decrease in research and development expenses of $1.4 million principally related to the reduction in costs incurred in connection with the preparation for our NDA filing for Contrave in the first quarter of 2011 as compared to same period in 2010. This overall decrease was partially offset by an increase in general and administrative expenses principally related to one-time corporate realignment costs.

Conference Call Today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to discuss the first quarter 2011 financial results and recent business highlights. The l
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
2. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
3. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
6. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
7. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
8. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
9. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
10. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
11. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  Elekta has CE ... Monaco® treatment planning system , enabling European clinics to ... major treatment techniques including advanced 3D planning, IMRT, VMAT ... Monaco ® ... well improved workflow efficiency. Advancements in 3D planning as ...
(Date:4/23/2015)... Calif., April 23, 2015  Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, today reported net income ... or $1.12 per diluted share.  Net income for the ... $0.56 per diluted share, and non-GAAP net income was ... Net sales for the quarter ended March 31, 2015 increased ...
(Date:4/23/2015)... - Health Canada is working with the Canadian manufacturers ... information regarding the risk of serious cardiovascular side effects ... used at high doses (at or above 2400 mg/day). ... Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) ... inflammation. The majority of ibuprofen products in ...
Breaking Medicine Technology:Elekta CE marks for Monaco v5.10 treatment planning system 2Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4
... Corporation ("Futuremed") (TSX: FMD) and Cardinal Health Canada Inc. ... Inc. (NYSE: CAH ), announced today that ... morning regarding Cardinal Health Canada,s proposed acquisition of all ... for CAD $8.15 per Common Share in cash (the ...
... WORTH, Texas, February 16, 2012 Medical ... in Fort Worth, Texas on March 14-15, 2012. In ... and MD&M East (Philadelphia, PA), MD&M Texas Conference is ... device design and development presented by experienced medtech industry ...
Cached Medicine Technology:Cardinal Health Canada Inc. Receives Competition Bureau Clearance for Acquisition of Futuremed 2Cardinal Health Canada Inc. Receives Competition Bureau Clearance for Acquisition of Futuremed 3Cardinal Health Canada Inc. Receives Competition Bureau Clearance for Acquisition of Futuremed 4Medical Design & Manufacturing Conference to be Launched in Texas in March 2012 2
(Date:4/25/2015)... (PRWEB) April 25, 2015 Parker and Sons ... and cooling, has spiked in Arizona alongside the growing economy. ... additional forty employees for April to help account for the ... forty employees in April is something we are enthusiastic about. ... said Paul Kelly, president at Parker and Sons. , Indeed, ...
(Date:4/25/2015)... 25, 2015 On Friday, April 17, ... Journal’s annual Best Implementation Award. This award is ... best use of RFID technology to improve its manufacturing, ... company that best demonstrates how RFID is delivering real ... RFID Journal Live! 2015 in San Diego, the RFID ...
(Date:4/24/2015)... York, NY (PRWEB) April 24, 2015 ... sober living residence in Westchester County. Just 35 miles ... help transition individuals back into everyday life while recovering ... Thursday, May 7, 2015, will allow therapists, doctors and ... areas and learn more about the opportunities offered by ...
(Date:4/24/2015)... California (PRWEB) April 24, 2015 Ryadon ... a wide range of capabilities and services to complement ... , Ryadon's Quantity Discount Program will be offered on ... follows: , Order 4-19: Receive 10% discount - Order ... by Using the Drawer Slides Products, ...
(Date:4/24/2015)... York (PRWEB) April 24, 2015 ... move forward in the federal multidistrict litigation underway ... According to court documents, the parties involved in ... April 16th detailing, among other things, preparation for ... that counsel for both plaintiffs and defendants have ...
Breaking Medicine News(10 mins):Health News:Parker and Sons Plans to Expand in 2015 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... have an occasional "bad day" are at increased risk of ... ,It is not uncommon for people over age 70 to ... least half a day and/or cutting back on usual activities ... this is just a normal sign of aging and not ...
... women with endometriosis may one day lead to new ... new research suggests. What's more, the researchers may have ... unfortunate consequence of the condition. ,Anywhere from 10 to ... occurs when the tissue //that lines the uterus, the ...
... biopsy will tell you it’s not a pleasant experience. Now ... for prostate cancer and eliminate the need for unnecessary biopsies ... his prostate after blood tests revealed elevated levels of PSA ... prostate cancer. "Every time they take a section through the ...
... The first major conference on the deadly SARS epidemic ... today. More than 1,000 scientists and clinicians gathered to ... scientific findings and talk about control strategies for a ... infected 8,460. ,The meeting in Kuala Lumpur will also ...
... including non-smokers, are misusing nicotine patches and gum. The authors ... up for health trouble if they smoke and use the ... use the products to maintain their nicotine levels. ,But an ... have lied on the survey. And even if they weren't, ...
... study shows young children with high cholesterol levels are ... and adulthood. Researchers studied the eating habits and cholesterol ... years. The children were examined by doctors and had ... cholesterol, measured periodically. ,Results of the study show children ...
Cached Medicine News:Health News:Teens Misusing Nicotine-Replacement Products 2
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
Medicine Products: